摘要
目的帕金森病异动症在帕金森病患者中有很高的发生率,本文拟探讨帕金森病异动症的合理药物选择及疗效。方法:收集我院诊断为帕金森病异动症的患者,分为:50例研究组(服用吡贝地尔缓释片+左旋多巴)和50例对照组(服用金刚烷胺+左旋多巴)。对比两组治疗不同时期帕金森统一评分量表。两组治疗疗效。两组药物服用安全性。结果研究组和对照组药物治疗疗效分别为98%、86%,结果比较有差异(P<0.05);两组患者治疗前帕金森统一评分量表评分比较无差异(P>0.05);组间相比,治疗后研究组帕金森统一评分量表评分低于对照组,比较有差异,组内相比,治疗后研究组帕金森统一评分量表评分降幅大于对照组,结果比较有差异(P<0.05);研究组药物服用后出现2例消化道不适(1例恶心、1例呕吐)、1例直立性低血压,对照组药物服用后出现4例口干、5例便秘,研究组和对照组不良反应发生率分别为6%、18%,结果比较有差异(P<0.05)。结论吡贝地尔缓释片治疗帕金森病异动症疗效肯定,安全性好,值得临床推广。
Objective Parkinson’s disease dyskinesia has a high incidence in patients with Parkinson’s disease.This paper intends to explore the rational drug selection and efficacy of Parkinson’s disease dyskinesia. Methods Patients with Parkinson’s disease dysplasia were enrolled in our study.They were divided into 50 study groups（taking piredilide sustained-release tablets ＋ levodopa） and 50 control groups（taking amantadine ＋ levodopa）.The Parkinson’s Unified Rating Scale was compared between the two groups for different periods of treatment.The treatment efficacy of the two groups. The safety of the two groups of drugs was taken. Results The therapeutic effects of the study group and the control group were 98% and 86%, respectively.The results were different（P〈 0.05）. There was no difference in the scores of the Parkinson’s Unified Rating Scale before treatment（P〉 0.05）.Compared with the control group,the Parkinson’s Unified Rating Scale score was lower than that of the control group.The score of the Parkinson’s Unified Rating Scale decreased after the treatment compared with the control group.The results were different（P〈 0.05）;2 cases of digestive tract discomfort（1 nausea, 1 vomiting） and 1 case of orthostatic hypotension occurred in the study group.Four cases of dry mouth and 5 cases of constipation occurred in the control group.The incidence of adverse reactions in the control group and the control group were 6% and 18%, respectively,and the results were different（P〈 0.05）. Conclusion The efficacy of piredilil sustained-release tablets in the treatment of Parkinson’s disease dysfunction is positive,safe and worthy of clinical promotion.
作者
杜杰
DU Jie(Department of Neurology,Kaizhou District People＇s Hospital,Chongqing 40540)
出处
《智慧健康》
2018年第19期87-88,90,共3页
Smart Healthcare
关键词
帕金森病
异动症
药物
Parkinson’s disease
Dyskinesia
Drug
